ClinicalTrials.gg
RecruitingNCT06926075ADVICEUpdated Mar 17, 2026

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

A Phase 1/2 interventional study of A novel hGIIA-Vimentin Inhibitor and Dose expansion in Prostate Cancers, Breast Cancer and Lung Cancers, sponsored by Filamon LTD. Recruiting at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Filamon LTD · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 260 studies in Prostatic Neoplasms with a site in Australia — 70 open to participants now, 134 under way, 41 of them phase 3. Prostatic Neoplasms · Australia.

Planned enrollment
171st of 245
80 · median 232
Started
2025
with 27 others
Phase 1/2
27 of 260
17 open now
Primary completion
2027-10
later than 77 of 133 live
Registered
223rd of 260
by date

Among the 260 studies in Prostatic Neoplasms with a site in Australia, this one is the 171st largest by planned enrollment of the 245 interventional ones that give a count, is one of 28 that started in 2025, is one of 27 in phase 1/2, reaches primary completion later than 77 of the 133 other live ones, and was the 223rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

70 of the 260 studies in Prostatic Neoplasms with a site in Australia are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Prostatic Neoplasms with a site in Australia, or all of them as a file.
02

Study summary

This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers.

It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II.

Primary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers.

Secondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.

Read the detailed description

This clinical trial is an adaptive phase I/II study of KESONOTIDE™, a novel hGIIA-vimentin inhibitor in participants with solid tumours.

This is a multicentre, open-label Phase I/II clinical trial. Phase I part of the study is a classic 3+3 dose escalation to identify the Maximum Tolerated Dose, Recommended Phase 2 Dose and Optimal Biological Dose.

In the Phase II study, participants will be given one of the two recommended dose levels. This may be as monotherapy or in combination with standard of care.

The study treatment will be a 21-day treatment Cycle (once every 3 weeks) and KESONOTIDE™ will be orally administered. Study treatment will continue until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent, lost to follow-up or another discontinuation criterion.

This trial will utilise an adaptive design which permits treatment arm modification or early stopping for efficacy or futility.

03

Conditions studied

  • Prostate Cancers
  • Breast Cancer
  • Lung Cancers
  • Ovarian Cancer
  • Glioblastoma Multiforme (GBM)
  • Pancreas Cancer
  • Skin Cancer

Keywords

  • kesonotide, vimentin inhibotor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of ).
  • Has an performance status score of 0 or 1.
  • Has a of > 12 weeks in the opinion of the investigator.
  • Measurable or evaluable disease by CT/MRI according to v1.1, except for prostate and breast cancer (bone only are acceptable) and glioma.
  • or cytologically confirmed locally advanced/metastatic solid cancers.
  • Has adequate organ function within 7 days prior to Day 1 of Cycle 1, defined as below:
  • Laboratory Value
  • Hematology
  • count > 100 x 109/L
  • > 9.0 g/dL
  • > 1.5 x 109/L
  • Renal Function
  • Creatinine \< 1.5 x
  • Hepatic Function
  • and ALT \< 3 x ULN for the reference laboratory or \< 5 x ULN in the presence of liver metastases
  • Total ≤ 1.5 x ULN
  • Serum albumin ≥ 2.5 g/dL
  • /PT and APTT ≤ 1.5 x ULN
  • Male and female participants of reproductive/ must agree to use adequate methods (e.g., double barrier or intrauterine contraceptive) for at least 90 days during the study and after the last dose of study drug.
  • Male participants must not freeze or donate sperm starting at screening and throughout the study period, and at least 90 days after the final study drug administration.
  • Female participants must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and at least 90 days after the final study drug administration.
  • Has failed standard of care or refused next line therapy at the present time and if approved treatment options are still available, can delay approved treatments without harm as judged by the investigator (e.g., patients requesting a break between ).

Additional Inclusion Criteria for Parts 2 and 3:

  • (as defined for Part 1) or recognised and abnormal biomarker levels (e.g., PSA for prostate cancer, CA15.3 for breast cancer).
  • Defined diseases or disease states of interest, suitable for dose expansion.
  • Patients who have enrolled in Part 1 of the study (dose-escalation), and in the opinion of the investigator, are benefitting from treatment, may be eligible for Parts 2 and 3.

Exclusion criteria

Exclusion Criteria:

  • Participants who are unable to cease any anti-inflammatory medications or statins prior to and during the study, including non-steroidal anti-inflammatories, oral at any dose; topical steroids and anti-inflammatories are allowable.
  • Participants who have participated in other clinical trials and received products within 4 weeks, or within five half-lives of the treatment, whichever is longer, before Cycle 1 Day 1 of the study period.
  • Previous adverse reactions which have not returned to Grade 0 or 1 according to v5.0 (except alopecia and fatigue) at the screening visit.
  • A active infection determined by the investigator.
  • Significant or recurrent third space accumulation (e.g., ascites or pleural effusions) according to the investigator.
  • Has a medical history of myocardial infraction or unstable angina within 6 months before enrolment.
  • Has a medical history of symptomatic CHF ( (NYHA) classes II-IV) or serious cardiac arrhythmia requiring treatment.
  • Has a history or presence of uncontrolled mental illness.
  • The participant is expected to be non-compliant with critical trial procedures and is not willing or able to adhere to the trial requirements during the study.
  • Participants are deemed inappropriate for this clinical trial at the discretion of the investigator.

Additional Exclusion Criteria for Parts 2 and 3:

- Patients must not have more than 2 .

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Phase I, Single Arm, dose escalation

    Drug: A novel hGIIA-Vimentin Inhibitor · Drug: Dose expansion

  • Experimental
    2 Arms of selected indication and recommended dose

    Drug: A novel hGIIA-Vimentin Inhibitor · Drug: Dose expansion

Interventions

  • DrugA novel hGIIA-Vimentin Inhibitor

    Phase I, dose escalation includes 4 increasing doses, 10mg, 30mg, 60mg and 120mg.

  • DrugDose expansion

    Phase II will enrol participants in selected indication(s) and will be given one of the two recommended doses by the SMC.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability (Incidence of SAEs) of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers.

    Incidence of serious adverse events (SAEs)

    Time frame: Cycle 1 (21 days)

  2. To evaluate the safety and tolerability (Treatment emergent adverse effects) of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers.

    Treatment emergent adverse effects (TEAEs)

    Time frame: Cycle 1 (21 days)

  3. To evaluate the safety and tolerability (Incidence and nature of DLTs) of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers.

    Incidence and nature of dose-limiting toxicities (DLTs).

    Time frame: Cycle 1 (21 days)

  4. To evaluate the safety and tolerability (Changes in vital signs/Heart Rate bpm) of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers.

    Changes in vital sign measurements (Hear rate in beats per minute)

    Time frame: Cycle 1 (21 days)

  5. To evaluate the safety and tolerability (Clinical safety laboratory parameters) of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers.

    Clinical safety laboratory parameters (abnormal haematology, clinical chemistry and coagulation blood tests; pregnancy test, as per CTCAE v5.0 classification

    Time frame: Cycle 1 (21 days)

  6. To evaluate the safety and tolerability (ECG parameters) of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers.

    Electrocardiogram (ECG) parameters (Heart Rate, PR Interval, P wave, QRS Complex, T wave, ST Segment, QT Interval) where combined parameters make up a full ECG tracing results

    Time frame: Cycle 1 (21 days)

  7. To evaluate the safety and tolerability (ECOG performance status) of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers.

    Eastern Cooperative Oncology Group (ECOG) performance status findings.

    Time frame: Cycle 1 (21 days)

  8. To evaluate the safety and tolerability (Changes in vital signs/Blood Pressure) of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers.

    Changes in vital sign measurements (blood pressure in systolic and diastolic mm Hg)

    Time frame: Cycle 1 (21 days)

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2027, 23 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 23 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Apr 13, 2025
StartActual
Nov 7, 2025
Primary completionEst.
Oct 26, 2027
CompletionEst.
Oct 26, 2027
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06926075
Lead sponsor
Filamon LTD
Responsible party
Sponsor
First posted
Apr 13, 2025
Start date
Nov 7, 2025
Primary completion
Oct 26, 2027 (estimated)
Completion
Oct 26, 2027 (estimated)
Last update
Mar 17, 2026

Study contacts

Admir Huseincehajic
Contact
admir.huseincehajic@filamon.com
+61467451064
Graham Kelly
Contact
graham.kelly@filamon.com
+61 429 854 390

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion